Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Brief Summary: The purpose of this study is to evaluate the safety and antiviral activity of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) with and without ribavirin (RBV) in patients with chronic hepatitis C virus genotype 1b (HCV GT1b) infection without cirrhosis.


Options:
A: Arm Label: ABT-450/r/ABT-267 and ABT-333, plus RBV for 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Ribavirin (RBV) | Arm Label: ABT-450/r/ABT-267 and ABT-333, plus RBV for 24 weeks; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Ribavirin (RBV) | Intervention Type: DRUG; Name: ABT-450/r/ABT-267, ABT-333; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, plus RBV for 12 weeks, ABT-450/r/ABT-267 and ABT-333, plus RBV for 24 weeks | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, plus RBV for 12 weeks, ABT-450/r/ABT-267 and ABT-333, plus RBV for 24 weeks
B: Arm Label: PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ribavirin, Drug: Pegylated Interferon Alfa 2a, Other: Placebo | Arm Label: Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Ribavirin, Drug: Pegylated Interferon Alfa 2a | Arm Label: Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Ribavirin, Drug: Pegylated Interferon Alfa 2a | Arm Label: Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Ribavirin, Drug: Pegylated Interferon Alfa 2a | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week | Intervention Type: DRUG; Name: Pegylated Interferon Alfa 2a; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week
C: Arm Label: ABT-450/r/ABT-267 and ABT-333, Plus RBV; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Ribavirin | Arm Label: ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Placebo for ribavirin | Intervention Type: DRUG; Name: ABT-450/r/ABT-267, ABT-333; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV, ABT-450/r/ABT-267 and ABT-333, Plus RBV | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus RBV | Intervention Type: DRUG; Name: Placebo for ribavirin; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV
D: Arm Label: GT1 HCV 10-mg Elbasvir (Panel A); Type: EXPERIMENTAL; Interventions: Drug: Elbasvir, Drug: Placebo | Arm Label: GTI HCV 50-g Elbasvir (Panel B); Type: EXPERIMENTAL; Interventions: Drug: Elbasvir, Drug: Placebo | Arm Label: GT1 HCV 5-mg Elbavir (Panel C); Type: EXPERIMENTAL; Interventions: Drug: Elbasvir, Drug: Placebo | Arm Label: GT1 HCV 200-mg Elbasvir (Panel D); Type: EXPERIMENTAL; Interventions: Drug: Elbasvir, Drug: Placebo | Arm Label: GT3 HCV 10-mg Elbasvir (Panel E); Type: EXPERIMENTAL; Interventions: Drug: Elbasvir, Drug: Placebo | Arm Label: GT3 HCV 50-mg Elbasvir (Panel F); Type: EXPERIMENTAL; Interventions: Drug: Elbasvir, Drug: Placebo | Arm Label: GT3 HCV 100-mg Elbasvir (Panel G); Type: EXPERIMENTAL; Interventions: Drug: Elbasvir, Drug: Placebo | Arm Label: GT3 HCV 200-mg Elbasvir (Panel H); Type: EXPERIMENTAL; Interventions: Drug: Elbasvir, Drug: Placebo | Arm Label: GT1a HCV 10-mg Elbasvir (Panel I); Type: EXPERIMENTAL; Interventions: Drug: Elbasvir, Drug: Placebo | Arm Label: GT1a HCV 50-mg Elbasvir (Panel J); Type: EXPERIMENTAL; Interventions: Drug: Elbasvir, Drug: Placebo | Intervention Type: DRUG; Name: Elbasvir; Assigned to Arm(s): GT1 HCV 10-mg Elbasvir (Panel A), GT1 HCV 200-mg Elbasvir (Panel D), GT1 HCV 5-mg Elbavir (Panel C), GT1a HCV 10-mg Elbasvir (Panel I), GT1a HCV 50-mg Elbasvir (Panel J), GT3 HCV 10-mg Elbasvir (Panel E), GT3 HCV 100-mg Elbasvir (Panel G), GT3 HCV 200-mg Elbasvir (Panel H), GT3 HCV 50-mg Elbasvir (Panel F), GTI HCV 50-g Elbasvir (Panel B) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): GT1 HCV 10-mg Elbasvir (Panel A), GT1 HCV 200-mg Elbasvir (Panel D), GT1 HCV 5-mg Elbavir (Panel C), GT1a HCV 10-mg Elbasvir (Panel I), GT1a HCV 50-mg Elbasvir (Panel J), GT3 HCV 10-mg Elbasvir (Panel E), GT3 HCV 100-mg Elbasvir (Panel G), GT3 HCV 200-mg Elbasvir (Panel H), GT3 HCV 50-mg Elbasvir (Panel F), GTI HCV 50-g Elbasvir (Panel B)

Answer: C